100
Participants
Start Date
October 27, 2024
Primary Completion Date
May 8, 2025
Study Completion Date
May 8, 2025
Baloxavir Marboxil
Baloxavir marboxil will be administered as oral suspension: 2 milligrams per kilograms (mg/kg) (if weight \< 20 kg), 40 mg (if weight ≥ 20 kg to \< 80 kg), or 80 mg (if weight ≥ 80 kg).
Oseltamivir
Oseltamivir will be administered as oral capsule: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≥ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
Liaocheng people's Hospital, Liaocheng
Ningbo Women and Children's Hospital, Ningbo
Xiamen Maternal and Child Health Hospital, Xiamen
Chongqing University Jiangjin Hospital, Chongqing
Peoples Hospital of Hunan Province, Changsha
Hunan Provincial Maternal and Child Health Care Hospital, Changsha
The Second Affiliated Hospital of Shantou University Medical College, Shantou
University of Chinese Academy of Sciences Shenzhen Hospital, Shenzhen
Liuzhou People's Hospital, Liuzhou
The Third People's Hospital of Hainan Province, Sanya
Chengdu Women's and Children's Central Hospital, Chengdu
The First People's Hospital of Changde, Changde
Childern's Hospital of Chongqing Medical University, Chongqing
Sanmenxia Central Hospital, Sanmenxia
The First Affiliated Hospital, Shaoyang University, Shaoyang
Yuncheng Central Hospital, Yuncheng
Cnpc Central Hospital, Langfang
Linfen Central Hospital, Linfen
Hoffmann-La Roche
INDUSTRY